Overview

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), is currently being studied in a Phase 1/2 clinical trial for the treatment of recurrent, metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

 

Latest Presentation

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Events & Presentations

SEC Filings

Filing date Description Form

Report of unscheduled material events or corporate event

 8-K

Initial filing by director officer or owner of more than ten percent.

 3

Statement of changes in beneficial ownership of securities

 4